New York, June 2, 2026, 13:09 (EDT)
Option Care Health ticked just above flat Tuesday afternoon after the home-infusion provider said it was ranked No. 15 on TIME’s 2026 list of the world’s most impactful companies.
The stock traded 0.1% higher at $20.49, volume near 528,000 shares. It moved between $20.21 and $20.64. The QQQ ETF, which tracks the Nasdaq, gained 0.4%. Health Care Select Sector SPDR Fund, which covers the sector, slipped 1.1%.
That’s important now as investors try to figure out if April’s weaker revenue was a blip or the beginning of a longer slowdown. The company’s Q1 numbers had revenue up just 1.3% from last year and adjusted EBITDA down 6.3%. Option Care Health, Inc.
Option Care said Monday it landed 15th on TIME and Statista’s 2026 list ranking companies by measurable positive impact on society, the environment and economy. CEO John C. Rademacher said the company’s purpose is to provide “extraordinary care that changes lives” and added, “behind every dose dispensed and every nursing visit is a loved one.” Option Care Health, Inc.
TIME put together the list working with Statista, using net-impact numbers pulled from The Upright Project. It factored in economic scale, United Nations Sustainable Development Goals, and science-based social and environmental impacts. Time
Investors didn’t do much with the stock. Reputation matters in healthcare, since payers and hospitals affect where patients go, but on Tuesday investors kept an eye on growth, reimbursement, and the slow chronic-therapy business called out in the first-quarter update.
Rademacher said after the April report that management was “not satisfied with our revenue growth momentum” and was “taking decisive actions” to get the business growing faster. Option Care now sees 2026 revenue at $5.675 billion to $5.775 billion, adjusted diluted EPS of $1.82 to $1.92, and adjusted EBITDA between $480 million and $505 million. Option Care Health, Inc.
Wall Street analysts are still divided, though most aren’t negative. MarketBeat data on Tuesday put the average rating at “Moderate Buy” from 13 analysts, with a 12-month average target of $31.25. Still, there were several target cuts in May after earnings, with JPMorgan, Barrington, UBS, TD Cowen and Bank of America all lowering their estimates, according to MarketBeat. MarketBeat
The field is crowded. Option Care’s 2025 10-K lists Optum Infusion Pharmacy under UnitedHealth Group, CVS Health’s Coram, BrightSpring’s Amerita, and KabaFusion as competitors in a fragmented space for home and alternate-site infusion. The market weighs care quality, pricing, payer contracts, and reliability. SEC
CVS has found it tough going. Reuters said in 2024 that CVS would quit its main infusion-services unit, shut or sell 29 regional pharmacies, and halt new patient intake for certain IV treatments. Some specialty drugs and nursing services would stay. Reuters
The risks are clear. If demand for chronic therapy remains weak, or if payers take longer to approve, and as pricing pressure or tighter drug supply relationships hit, Option Care’s buybacks and cost controls may not keep up with slower growth. The 10-K shows four vendors made up around 68% of its drug and supply buys in 2025. It also lists payer ties, rules, changes in the drug business and reimbursement standards as risks. SEC
The stock still trades like a turnaround play, not like it’s getting a valuation boost. The TIME ranking is a win on the PR front, but any real move in the shares probably needs real signs of revenue picking up again.
